Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pacira BioSciences's share price for the quarter that ended in Mar. 2026 was €19.4. Pacira BioSciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 39.3 Mil. Therefore, Pacira BioSciences's market cap for the quarter that ended in Mar. 2026 was €762.6 Mil.
Pacira BioSciences's quarterly market cap
declined
from Sep. 2025 (€910.9 Mil) to Dec. 2025 (€888.1 Mil) and
declined
from Dec. 2025 (€888.1 Mil) to Mar. 2026 (€762.6 Mil).
Pacira BioSciences's annual market cap
declined
from Dec. 2023 (€1,385.1 Mil) to Dec. 2024 (€855.5 Mil) but then
increased
from Dec. 2024 (€855.5 Mil) to Dec. 2025 (€888.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pacira BioSciences's Enterprise Value for Today is €1,083.2 Mil.
Pacira BioSciences (STU:82P) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pacira BioSciences Market Cap Related Terms
Pacira BioSciences Market Cap Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:82P vs ALVO, BIOA, COLL: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pacira BioSciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (STU:82P) has a Market Cap of €901.8 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pacira BioSciences and its competitors. According to the industry distribution chart, Pacira BioSciences ranks #249 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Pacira BioSciences' Market Cap too high?
Pacira BioSciences' current Market Cap is €901.8 Mil. Based on the distribution chart, Pacira BioSciences ranks #249 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Market Cap compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #249 out of 1024 companies for Market Cap. This places Pacira BioSciences in the top 24% of its industry — outperforming the majority of peers. The industry median Market Cap is 210.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.63, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Market Cap is €901.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (STU:82P) is currently considered Modestly Undervalued. The stock's GF Value™ is €25.82, compared to a current price of €22.80 — trading 11.7% below its estimated fair value. The current Market Cap is €901.8 Mil. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Pacira BioSciences (STU:82P), the current Market Cap is €901.8 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (STU:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.80 is trading 11.7% below its estimated GF Value™ of €25.82.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for STU:82P:
Market Cap: €901.8 Mil
GF Value™: €25.82 vs. price of €22.80 (11.7% below fair value)
No single metric tells the full story. See the STU:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for STU:82P
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:82P has been successfully added to your 
